Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 13, 2024
Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology company developing universally implantable, bioengineered human tissue, will release its Q2 2024 financial results on August 13, 2024. The company will host a webcast and conference call at 8:30 a.m. ET to discuss recent corporate updates from its acellular tissue engineered vessel (ATEV) programs. Investors can join via phone (U.S.: 1-877-704-4453, International: 1-201-389-0920, Conference ID: 13747913) or webcast. A replay will be available on the company's investor website for at least 30 days after the event.
Humacyte, Inc. (Nasdaq: HUMA), un'azienda di biotecnologie in fase clinica che sviluppa tessuti umani bioingegnerizzati universalmente impiantabili, pubblicherà i suoi risultati finanziari del Q2 2024 il 13 agosto 2024. L'azienda ospiterà un webcast e una conferenza telefonica alle 8:30 a.m. ET per discutere gli aggiornamenti recenti relativi ai suoi programmi di vasi ingegnerizzati acellulari (ATEV). Gli investitori possono partecipare via telefono (USA: 1-877-704-4453, Internazionale: 1-201-389-0920, ID Conferenza: 13747913) o tramite webcast. Una registrazione sarà disponibile sul sito web per investitori dell'azienda per almeno 30 giorni dopo l'evento.
Humacyte, Inc. (Nasdaq: HUMA), una empresa de biotecnología en etapa clínica que desarrolla tejidos humanos bioingeniería implantables de manera universal, publicará sus resultados financieros del Q2 2024 el 13 de agosto de 2024. La compañía organizará un webcast y una llamada de conferencia a las 8:30 a.m. ET para discutir las actualizaciones corporativas recientes de sus programas de vasos bioingenierizados acelulares (ATEV). Los inversores pueden unirse por teléfono (EE.UU.: 1-877-704-4453, Internacional: 1-201-389-0920, ID de Conferencia: 13747913) o por webcast. Una grabación estará disponible en el sitio web para inversores de la empresa durante al menos 30 días después del evento.
Humacyte, Inc. (Nasdaq: HUMA)는 보편적으로 이식 가능한 생체 공학 인간 조직을 개발하는 임상 단계의 생명공학 회사로, 2024년 2분기 재무 결과를 2024년 8월 13일 발표할 예정입니다. 회사는 최근 세포가 없는 조직 공학 혈관 (ATEV) 프로그램과 관련된 기업 업데이트를 논의하기 위해 동부 표준시 오전 8시 30분에 웹캐스트 및 컨퍼런스 콜을 개최합니다. 투자자들은 전화(미국: 1-877-704-4453, 국제: 1-201-389-0920, 컨퍼런스 ID: 13747913) 또는 웹캐스트를 통해 참여할 수 있습니다. 이벤트 후 최소 30일 동안 회사의 투자자 웹사이트에서 재방송이 제공될 예정입니다.
Humacyte, Inc. (Nasdaq: HUMA), une entreprise de biotechnologie en phase clinique développant des tissus humains bioingénierie universellement implantables, publiera ses résultats financiers du T2 2024 le 13 août 2024. L'entreprise organisera un webcast et une conférence téléphonique à 8h30 (ET) pour discuter des mises à jour récentes de ses programmes de vaisseaux bioingénierie acellulaires (ATEV). Les investisseurs peuvent participer par téléphone (États-Unis : 1-877-704-4453, International : 1-201-389-0920, ID de conférence : 13747913) ou par webcast. Un enregistrement sera disponible sur le site Web des investisseurs de l'entreprise pendant au moins 30 jours après l'événement.
Humacyte, Inc. (Nasdaq: HUMA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das universell implantierbare, bioengineerte menschliche Gewebe entwickelt, wird am 13. August 2024 seine finanziellen Ergebnisse für das Q2 2024 veröffentlichen. Das Unternehmen wird um 8:30 Uhr ET ein Webcast und eine Telefonkonferenz durchführen, um aktuelle Unternehmensupdates zu seinen zellfreien, bioengineerten Gefäßen (ATEV)-Programmen zu besprechen. Investoren können telefonisch teilnehmen (USA: 1-877-704-4453, International: 1-201-389-0920, Konferenz-ID: 13747913) oder über den Webcast. Eine Wiederholung wird mindestens 30 Tage nach der Veranstaltung auf der Investorenseite des Unternehmens verfügbar sein.
- None.
- None.
DURHAM, N.C., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the second quarter ended June 30, 2024, on Tuesday, August 13, 2024. Management will host a webcast and conference call at 8:30 a.m. ET to discuss recent corporate updates from its acellular tissue engineered vessel (ATEV) programs.
| Title: | Humacyte Second Quarter 2024 Financial Results and Corporate Update |
| Date: | August 13, 2024 |
| Time: | 8:30 AM Eastern Time |
| Conference Call Details: | 1-877-704-4453 (U.S. Investors Dial) 1-201-389-0920 (International Investors Dial) 13747913 (Conference ID) |
| Call me™ Feature: | Click Here |
| Webcast: | Webcast Link - Click Here |
The webcast should be accessible 15 minutes prior to the conference call’s start time. A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the investors section of the Company’s website for at least 30 days.
About Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s initial product candidates, a portfolio of ATEVs, are currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous (AV) access for hemodialysis, and peripheral artery disease. A Biologics License Application for the ATEV in the vascular trauma indication is currently under review by the FDA and was granted Priority Review with a PDUFA date of August 10, 2024. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received an RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.
Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com
Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com
FAQ
When will Humacyte (HUMA) release its Q2 2024 financial results?
What time is Humacyte's (HUMA) Q2 2024 earnings call scheduled for?
How can investors access Humacyte's (HUMA) Q2 2024 earnings call?
What will be discussed during Humacyte's (HUMA) Q2 2024 earnings call?
